Is Adcetris a chemotherapy drug?
Adcetris is a targeted drug used to treat cancer but is not a traditional chemotherapy. Adcetris is made up of 3 parts:
- an antibody that finds the protein CD30 on cancer cells
- an anticancer (chemotherapy) drug (that causes cell death)
- a “linker”, which attaches the cancer drug to the antibody so the drug can be released inside the cancer cell.
Adcetris combines the antibody and cancer drug, allowing the antibody to direct the drug to a target on lymphoma cancer cells known as CD30. The cancer drug is monomethyl auristatin E (MMAE), which inhibits microtubule polymerization and leads to cell death.
What type of drug is Adcetris?
Adcetris is known as a CD30-directed Antibody Drug conjugate (ADC). It belongs to a group of targeted drug therapies called monoclonal antibodies.
What does Adcetris treat?
Adcetris (brentuximab vedotin) is a prescription drug used in adults and children to treat different types of blood cancers (lymphomas). Adcetris is used to treat certain forms of classical Hodgkin lymphoma (cHL) and T-cell lymphomas (a form of non-Hodgkin lymphoma).
It is given as an intravenous (IV) infusion into your vein. Specifically Adcetris treats:
Classical Hodgkin Lymphoma:
- Adults with previously untreated Stage 3 or 4 classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine.
- Adults with classical Hodgkin lymphoma (cHL) at high risk of relapse (coming back) or progression (getting worse) after a stem cell transplant.
- Adults with classical Hodgkin lymphoma (cHL) after failure of a stem cell transplant OR after failure of treatment with at least 2 chemotherapy regimens (if you are not a stem cell transplant candidate).
- Previously untreated high risk classical Hodgkin lymphoma (cHL) in pediatric patients 2 years and older, in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide.
Certain types of B-cell lymphoma in adults:
- Relapsed (where the cancer has either returned after initial treatment) or refractory (has not responded to initial treatment) large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) NOS (not otherwise specified), DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for auto-HSCT or CAR T-cell therapy, in combination with lenalidomide and a rituximab product.
Certain types of T-cell lymphoma in adults:
- Systemic (throughout the body) anaplastic large cell lymphoma or other untreated peripheral T-cell lymphomas, in combination with cyclophosphamide, doxorubicin, and prednisone.
- Systemic primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.
- Primary cutaneous anaplastic large cell lymphoma or CD30- expressing mycosis fungoides (MF) in patients who have been treated with drug therapy that affects the whole body.
This is not all the information you need to know about Adcetris (brentuximab vedotin) for safe and effective use and does not take the place of your doctor’s directions. Review the full prouct information and discuss this information and any questions you have with your doctor or other health care provider.
Related questions
References
- Adcetris (brentuximab vedotin) prescribing information. Revised 2/2025. Accessed Feb 22, 2025 at https://labeling.pfizer.com/ShowLabeling.aspx?id=20629
- Bradley AM, Devine M, DeRemer D. Brentuximab vedotin: an anti-CD30 antibody-drug conjugate. Am J Health Syst Pharm. 2013 Apr 1;70(7):589-97. doi: 10.2146/ajhp110608. PMID: 23515511.
Read next
What is the success rate of Epkinly?
In the EPCORE NHL-1 trial, Epkinly delivered an overall response rate (ORR) of 61% with a median duration of response of 15.6 months in adults treated for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). In adults with R/R follicular lymphoma (FL), Epkinly demonstrated an 82% ORR, with more than 50% of patients still responsive at 14.8 months. Continue reading
What is the survival rate of Kymriah?
Studies are ongoing to monitor the survival rate of patients who received Kymriah (tisagenlecleucel) as a cancer treatment. Currently, the available data shows the survival rate is 87.7% for patients with relapsed or refractory follicular lymphoma at 24 months after the Kymriah infusion, and 43.6% for patients with aggressive B-cell non-Hodgkin’s lymphoma. The 5-year survival rate for patients with advanced B-cell advanced B-cell acute lymphoblastic leukemia is 55%. Continue reading
What is glofitamab?
Glofitamab-gxbm is an immunotherapy treatment that may be used to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after at least 2 lines of systemic therapy. It is approved under the name Columvi. Continue reading
See also:
Related medical questions
- What is the success rate of Breyanzi?
- How is Kymriah administered?
- How is Yescarta administered?
- What type of drug is Yescarta (axicabtagene ciloleucel)?
- Prednisone: What are 12 Things You Should Know?
- What is CAR T-cell therapy and how does it work?
- What are CHOP and R-CHOP chemotherapy regimens?
- What is the difference between Truxima and Rituxan?
- What is the success rate of Rituxan (rituximab) in patients with blood cancers?
- Does Truxima make you gain weight?
- What causes infusion reactions to rituximab?
- How does Monjuvi work?
- What is the difference between Rituxan and Rituxan Hycela?
- How is Monjuvi given / administered?
- How is Rituxan Hycela administered?
- What is the success rate of Monjuvi?
- What is the success rate of Keytruda?
- What is ABVD chemo regimen and how is it used for lymphoma?
- Is Velcade a type of chemotherapy?
- Is Imbruvica a chemotherapy drug?
- Does ibrutinib cause hair loss?
- How long does Velcade stay in your body?
- Who makes Imbruvica?
- How to pronounce Xalkori?
- How long does it take for Xalkori to work?
- Who makes Leukeran, and where is it made?
- What cancers are treated with Xalkori?
Drug information
- Adcetris Information for Consumers
- Adcetris prescribing info & package insert (for Health Professionals)
- Side Effects of Adcetris (detailed)
Related support groups
- Adcetris (2 questions, 5 members)
- B Cell Lymphoma (10 questions, 3 members)
- Diffuse Large B-Cell Lymphoma (19 questions, 3 members)
- Lymphoma (19 questions, 45 members)
- Non-Hodgkin's Lymphoma (18 questions, 39 members)
- Hodgkin's Lymphoma (11 questions, 13 members)
- Mycosis Fungoides (4 questions, 6 members)
- T Cell Lymphoma (2 questions, 3 members)